Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.-论文-万方医学网

第一作者： Joseph A,Sparano

第一单位： From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); University of Texas, San Antonio (P.M.R.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O., J.A.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); the National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and the University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and the University of Hawaii Cancer Center, Honolulu (J.L.B.).

作者： Joseph A,Sparano ^[1] ; Robert J,Gray ^[1] ; Peter M,Ravdin ^[1] ; Della F,Makower ^[1] ; Kathleen I,Pritchard ^[1] ; Kathy S,Albain ^[1] ; Daniel F,Hayes ^[1] ; Charles E,Geyer ^[1] ; Elizabeth C,Dees ^[1] ; Matthew P,Goetz ^[1] ; John A,Olson ^[1] ; Tracy,Lively ^[1] ; Sunil S,Badve ^[1] ; Thomas J,Saphner ^[1] ; Lynne I,Wagner ^[1] ; Timothy J,Whelan ^[1] ; Matthew J,Ellis ^[1] ; Soonmyung,Paik ^[1] ; William C,Wood ^[1] ; Maccon M,Keane ^[1] ; Henry L,Gomez Moreno ^[1] ; Pavan S,Reddy ^[1] ; Timothy F,Goggins ^[1] ; Ingrid A,Mayer ^[1] ; Adam M,Brufsky ^[1] ; Deborah L,Toppmeyer ^[1] ; Virginia G,Kaklamani ^[1] ; Jeffrey L,Berenberg ^[1] ; Jeffrey,Abrams ^[1] ; George W,Sledge ^[1]

作者单位： From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); University of Texas, San Antonio (P.M.R.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O., J.A.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); the National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and the University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and the University of Hawaii Cancer Center, Honolulu (J.L.B.). ^[1]

主题词成年人(Adult);年龄因素(Age Factors);老年人(Aged);算法(Algorithms);抗肿瘤药, 激素(Antineoplastic Agents, Hormonal);乳腺肿瘤(Breast Neoplasms);化学疗法, 辅助(Chemotherapy, Adjuvant);无病生存(Disease-Free Survival);雌激素拮抗剂(Estrogen Antagonists);女(雌)性(Female);基因表达谱(Gene Expression Profiling);人类(Humans);中年人(Middle Aged);肿瘤复发, 局部(Neoplasm Recurrence, Local);绝经前期(Premenopause);预后(Prognosis);比例危险度模型(Proportional Hazards Models);前瞻性研究(Prospective Studies);危险因素(Risk Factors);他莫昔芬(Tamoxifen)

DOI 10.1056/NEJMoa1904819

PMID 31157962

发布时间 2021-02-06

检索历史清除

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

The New England journal of medicine

相似文献

The New England journal of medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

The New England journal of medicine

相似文献

The New England journal of medicine

相关期刊

检索历史清除